Clinical trials: Liver Diseases, Alcoholic
Liver Diseases, Liver Fat
The Referral to Hepatology Can be Improved Through an Electronic Medical Record (EMR)-Based Best Practice Alert (BPA) for an Appropriate Referral
The purpose of this study is to promote the diagnosis and awareness of Non-Alcoholic Steatohepatitis (NASH) by linkage of care.
- Conditions
- Liver Diseases, Liver Fat, Diabetes Mellitus, Type 2, Non-Alcoholic Steatohepatitis
- Trial name
- NCT07580482
- Testing
- Best Practice Alert, No Intervention
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Kansas Medical Center
Non-Alcoholic Steatohepatitis (NASH)
Evaluating the Efficacy and Safety of Roflumilast in Patients with NASH
Study type :clinical trial Main purpose :esnsure safety and efficacy of Roflumilast to treat patients with Non-Alcoholic Steatohepatitis Background and aim: Non-alcoholic fatty liver disease is the most prevalent chronic liver…
- Trial name
- NCT06677788
- Testing
- Roflumilast 500 Mcg Oral Tablet, Vitamin E capsule
- Where
- Egypt
- Volunteers
- 55 people
- Sponsor
- Tanta University
Non-Alcoholic Fatty Liver Disease
Functional Roll for Non-alcoholic Fatty Liver Disease
Background: Low physical activity and poor eating habits (incl. high fat and carbohydrates but low fiber intake) are the main reason of obesity epidemic in western societies.
- Trial name
- NAFLDroll (NCT04520724)
- Testing
- plant fiber, maltodextrin bar
- Where
- Poland
- Volunteers
- 50 people
- Sponsor
- Pomeranian Medical University Szczecin
Non-alcoholic Fatty Liver Disease, Obesity
Magnetic Resonance Imaging (MRI) Fat Quantification of the Liver
Fatty liver in the obese is a common finding; some cases develop steato-hepatosis which in the long-term can lead to liver cirrhosis.
- Trial name
- NCT02682173
- Testing
- MR Abdomen
- Where
- Switzerland
- Volunteers
- 15 people
- Sponsor
- University Hospital, Basel, Switzerland
Nonalcoholic Fatty Liver Disease, Nonalcoholic Fatty Liver Disease (NAFLD)
The Impact of Pectin Supplementation on Systematic Inflammation Pathway, Gut Microbiome, and Metabolic Health in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
The goal of this clinical trial is to learn if daily supplementation with Low-methoxy (LM) pectin (polysaccharides extracted from citrus peels), which are commonly found in the UK diet (not pharmacological agents), can reduce…
- Conditions
- Nonalcoholic Fatty Liver Disease, Nonalcoholic Fatty Liver Disease (NAFLD), MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, MASLD
- Trial name
- PEC-MASLD (NCT07093346)
- Testing
- Pectin, Cocoa Powder, Magnetic Resonance Imaging with Contrast
- Where
- 3 sites in United Kingdom
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- University of Nottingham
Fatty Liver Disease, Type 2 Diabetes
Effect of Intermittent Calorie Restriction on MASLD Patients With Abnormal Glucose Metabolism
This study is designed to observe the effect of 5:2 intermittent calorie restriction (fasting 2 days each week) on liver fat content in MASLD patients with abnormal blood glucose.
- Conditions
- Fatty Liver Disease, Type 2 Diabetes, Impaired Glucose Regulation
- Trial name
- NCT04283942
- Testing
- Intermittent calorie restriction (ICR), Continuous calorie restriction (CCR)
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shanghai Zhongshan Hospital
Non-Alcoholic Fatty Liver Disease
The Effect of Coenzyme Q10 on Endothelial, Vascular and Myocardial Function
Non-alcoholic fatty liver disease (NAFLD) is associated with increased cardiovascular risk. The aim of this study is to investigate the effects of coenzyme Q10 (CoQ10) on endothelial, vascular and myocardial function in patients…
- Trial name
- NCT05941910
- Testing
- Q10
- Where
- Greece
- Volunteers
- 60 people
- Sponsor
- Attikon Hospital
Chronic Liver Disease, Fibrosis, Liver
Non Invasive Electrical Impedance Technology (EIT) for Diagnosing Liver Diseases Severity
The aims of this study are to assess the performance of the non-invasive Electrical Impedance Technology (EIT) in evaluating the liver fibrosis stage in patients with chronic liver diseases, in comparisons with a liver biopsy…
- Conditions
- Chronic Liver Disease, Fibrosis, Liver, Non-Alcoholic Fatty Liver Disease
- Trial name
- NCT03492879
- Testing
- EIT Technology
- Volunteers
- 210 people
- Sponsor
- Prof. Ziv Ben-Ari MD
Diabetes Mellitus Type 2
Medium-term Effects of a Polyphenol-rich Beverage Based on Red Grape Pomace Extract on Non-alcoholic Fatty Liver Disease, Cardiometabolic Risk Profile and Gut Microbiota in Subjects with Type 2 Diabetes
Nonalcoholic fatty liver disease (NAFLD) is a liver disease characterized by an abnormal accumulation of fat not due to alcohol or drug consumption that can evolve into steatohepatitis (NASH), fibrosis and cirrhosis.
- Trial name
- PoLiFat (NCT06895018)
- Testing
- Supplementation with Polyphenol Rich Drink
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- Federico II University
Nonalcoholic Fatty Liver Disease (NAFLD)
Cysteamine Bitartrate Delayed-Release for the Treatment of NAFLD in Children
CyNCh is a multi-center, placebo-controlled clinical trial of children ages 8 to 17 years with biopsy-confirmed moderate to severe nonalcoholic fatty liver disease (NAFLD).
- Trial name
- CyNCh (NCT01529268)
- Testing
- DR cysteamine bitartrate capsule
- Where
- 10 sites in United States
- Volunteers
- 169 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Fatty Liver
Liver Positron Emission Tomography (PET) Study of Non Alcoholic Fatty Liver Disease
The purpose of this study is to evaluate how the liver receives and uses fats for energy. This will help the investigators further understand the physical and chemical processes responsible for Non-Alcoholic Fatty Liver Disease…
- Trial name
- Liver (NCT00949403)
- Testing
- Radio pharmaceuticals C-11 Acetate, and C-11 Palmitate
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- Washington University School of Medicine
Steatohepatitis
A Study to Investigate Safety, Tolerability, and Pharmacokinetics of AZD7503 in Participants With Suspected NASH.
The purpose of this study is to measure the safety, tolerability, and PK (measurement of drug activity in the body over time) of AZD7503 injected subcutaneously, and compared to placebo, in participants with suspected NASH, a…
- Trial name
- NCT05864391
- Testing
- AZD7503
- Where
- 10 sites in United States, Puerto Rico
- Volunteers
- 40 people
- Sponsor
- AstraZeneca
Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis
Prevalence of NAFLD and Advanced Fibrosis in Patients With Type 1 Diabetes
The aim of this study is to assess the prevalence of nonalcoholic fatty liver disease (NAFLD) in patients with type 1 diabetes receiving care at Joslin clinic using noninvasive imaging and serum-based methods with the goal of…
- Conditions
- Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis, Fibrosis, Liver, Type 1 Diabetes
- Trial name
- NCT04595474
- Testing
- Transient Elastography
- Where
- United States
- Volunteers
- 533 people
- Sponsor
- Joslin Diabetes Center
Non-alcoholic Steatohepatitis
Investigate Safety, Tolerability, PK/PD of J2H-1702 in Healthy Females
Objectives: Primary objective_To evaluate the safety and tolerability after single oral administration of the investigational product (IP), J2H-1702 in healthy female subjects.
- Trial name
- NCT06308874
- Testing
- Amg dose administration group, Bmg dose administration group
- Where
- South Korea
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- J2H Biotech
NAFLD (Nonalcoholic Fatty Liver Disease), Hep A
Comparative Effects of Mediterranean and DASH Diet on Hepatic Function
Participants were assigned into three groups Control group recieving general dietary guidelines, Mediterranean diet intervention group DASH dietary intervention group
- Trial name
- NCT07622680
- Testing
- Dietary guidelines for fatty liver, Mediterranean diet, DASH diet
- Where
- Pakistan
- Volunteers
- 75 people
- Sponsor
- University of Lahore
Non-alcoholic Fatty Liver Disease
Focused Power Ultrasound Mediated Inferior Perirenal Adipose Tissue Modification Therapy for Non-Alcoholic Fatty Liver Disease (PARADISE-NAFLD)
This randomized, blinded, sham-control trial aims to evaluate the efficacy and safety of a novel focused power ultrasound mediated inferior perirenal adipose tissue modification therapy for non-alcoholic fatty liver disease.
- Trial name
- NCT06225713
- Testing
- focused power ultrasound mediated inferior perirenal adipose tissue modification
- Where
- 3 sites in China
- Volunteers
- 80 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Healthy, NAFLD
DDI Study of ASC41 in HV and the PK, Safety and Tolerability in Subjects With NAFLD.
The primary objective of this study is to evaluate the effect of itraconazole, a strong inhibitor)of cytochrome P4503A , and phenytoin a strong inducer of cytochrome P450 3A, CYP3A4, CYP1A2 and CYP2C19 on the pharmacokinetics of…
- Trial name
- NCT04845646
- Testing
- ASC41, Itraconazole, Phenytoin
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Gannex Pharma Co., Ltd.
Type 2 Diabetes, NAFLD
Diabetes Nutrition Algorithms in Patients With Overt Diabetes Mellitus
Basic treatment of type 2 diabetes should focus on diet, physical activity and lifestyle. Nevertheless, in early and late stage of T2DM, lifestyle intervention is mostly substituted by pharmacological intervention, although…
- Conditions
- Type 2 Diabetes, NAFLD, Obesity, Dyslipoproteinaemia
- Trial name
- DiNA-D (NCT02459496)
- Testing
- dietary consulting and advise
- Where
- 2 sites in Germany
- Volunteers
- 200 people
- Sponsor
- German Institute of Human Nutrition
NASH - Nonalcoholic Steatohepatitis
Effect of DMR in the Treatment of NASH
Non-alcoholic fatty liver disease (NAFLD) is a frequent disease affecting up to 25% of the USA population, 2-44% in Europe and up to 42,6-69,5% in patients with type 2 diabetes.
- Trial name
- DMR_NASH_001 (NCT03536650)
- Testing
- DMR
- Where
- Belgium
- Volunteers
- 14 people
- Sponsor
- Erasme University Hospital
NAFLD, Heart Failure
T1-mapping by Cardiovascular Magnetic Resonance Imaging to Assess Non-Alcoholic Fatty Liver Disease
On clinically indicated Cardiovascular Magnetic Resonance studies, native T1-times and extracellular volume of the liver will be assessed and findings correlated with established risk calculators for non-alcoholic fatty liver…
- Conditions
- NAFLD, Heart Failure, Valvular Disease, Coronary Disease
- Trial name
- NCT04220450
- Testing
- T1 mapping on Cardiovascular Magnetic Resonance Studies
- Where
- Austria
- Volunteers
- 800 people
- Sponsor
- Dr. Andreas Kammerlander
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.